


Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I):



wherein

Y^1 is CH or N;

Q^1 is selected from the group consisting of

- (1) $-OH$, and
- (2) $-NH_2$;

Q^2 and Q^3 independently selected from the group consisting of

- (1) hydrogen, and
- (2) halogen;

R^a is selected from the group consisting of

- (1) hydrogen,
- (2) $-C_{1-10}$ alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
- (3) $-C_{3-8}$ cycloalkyl;

R^b is selected from the group consisting of

- (1) hydrogen,
- (2) $-C_{1-10}$ alkyl,
- (3) $-C_{1-3}$ alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl,
- (4) $-C_{3-8}$ cycloalkyl,

wherein said cycloalkyl, alkyl and aryl are unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C₁₋₁₀ alkyl,

(5) -(CH₂)_n-NR^cR^d wherein R^c and R^d are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and n is 2, 3 or 4, and

(6) -(CH₂)_{n'}-O-R^e, wherein R^e is selected from the group consisting of

- (a) C₁₋₁₀ alkyl,
- (b) -C₀₋₃ alkyl-aryl, wherein said aryl is selected from the group consisting of phenyl and naphthyl, wherein said alkyl and aryl are unsubstituted or substituted with one or more
 - (i) halo,
 - (ii) -OH,
 - (iii) -CN,
 - (iv) -O-C₁₋₁₀ alkyl,

and n' is 1, 2, 3 or 4;

m is 1 or 2;

R¹ is (1) aryl selected from the group consisting of phenyl and naphthyl, or
(2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
(3) -C₁₋₁₀ alkyl, and
(4) -C₃₋₈ cycloalkyl,

wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C₁₋₁₀ alkyl,

- (e) $-C_{1-10}$ alkyl,
- (f) $-C_{3-8}$ cycloalkyl,
- (g) aryl selected from the group consisting of phenyl and naphthyl, or
- (h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

R^2 is selected from the group consisting of:

(1) $(R^4-SO_2)N(R^7)-$, wherein R^4 is

- (a) $-C_{1-10}$ alkyl,
- (b) $-C_{3-8}$ cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) $-OH$,
- (iii) $-CN$,
- (iv) $-O-C_{1-10}$ alkyl,
- (v) $-C_{1-10}$ alkyl,
- (vi) $-C_{3-8}$ cycloalkyl,
- (vii) aryl selected from the group consisting of phenyl and naphthyl, or
- (viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

and said aryl and heteroaryl is unsubstituted or substituted with one or more


- (A) halo,
- (B) $-OH$,
- (C) $-CN$,
- (D) $-O-C_{1-10}$ alkyl,
- (E) $-C_{3-8}$ cycloalkyl, or
- (F) $-C_{1-10}$ alkyl,

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl,
- (v) -C₃₋₈ cycloalkyl, or
- (vi) -C₁₋₁₀ alkyl,

(d) -(CH₂)_x-NR^fR^g wherein R^f and R^g are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and x is 0, 1, 2, 3 or 4, or R^f and R^g, together with the nitrogen atom to which they are attached form the group



wherein y is 1 or 2, Y⁵ is -CHR²¹, -O- or NR²¹, wherein R²¹ is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C₁₋₁₀ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C₁₋₁₀ alkyl, or
- (E) -C₃₋₈ cycloalkyl;

R⁷ is selected from the group consisting of

- (a) hydrogen, and
- (b) -C₁₋₁₀ alkyl,
- (c) aryl selected from the group consisting of phenyl and naphthyl, or
- (d) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl.


wherein said alkyl, aryl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl,
- (v) -C₃₋₈ cycloalkyl,
- (vi) aryl selected from the group consisting of phenyl and naphthyl, or
- (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl,

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C₁₋₁₀ alkyl,
- (E) -C₃₋₈ cycloalkyl, or
- (F) aryl selected from the group consisting of phenyl and naphthyl;

(e) -(CH₂)_y'-NR^hRⁱ wherein R^h and Rⁱ are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and y' is 1, 2, 3 or 4, or or R^h and Rⁱ, together with the nitrogen atom to which they are attached from the group



wherein y' is 1 or 2, Y^6 is $-\text{CHR}^{22}$, $-\text{O}-$ or NR^{22} , wherein R^{22} is selected from the group consisting of;

(i) hydrogen, and

(ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

(A) halo,

(B) $-\text{OH}$,


(C) $-\text{CN}$,

(D) $-\text{O}-\text{C}_{1-10}$ alkyl, or

(E) $-\text{C}_{3-8}$ cycloalkyl,


or R^4 and R^7 are linked together to form the group

(a)




wherein z is 1, 2 or 3; or

(b)



wherein z is 1, 2 or 3


(2)



wherein R⁸ is selected from the group consisting of


- (a) -CN,
- (b) hydrogen, and
- (c) tetrazolyl;

(3)




wherein o is 1, 2, 3 or 4; and

(4)



wherein Y² is -NH=CH- or -CH=NH-;

R³ is selected from the group consisting of



wherein Y³ is CR^{6c} or N;

R⁵ is C₁₋₁₀ alkyl or C₁₋₂ perfluoroalkyl;

R^{6a}, R^{6b}, and R^{6c} are independently selected from the group consisting of:

- (1) hydrogen,

- (2) halo,
- (3) $-C_{1-10}$ alkyl,
- (4) $-OH$,
- (5) $-CN$,
- (6) $-C_{3-8}$ cycloalkyl, and
- (7) $-O-C_{1-10}$ alkyl;


R^9 and R^{10} are independently selected from the group consisting of

- (1) hydrogen,
- (2) $-C_{1-10}$ alkyl, and
- (3) $-C_{3-8}$ cycloalkyl,

wherein said alkyl and cycloalkyl are unsubstituted or substituted with one or more

- (a) halo,
- (b) $-OH$,
- (c) $-CN$,
- (d) $-O-C_{1-10}$ alkyl,
- (e) $-C_{3-8}$ cycloalkyl, and
- (f) $-NR^j R^k$ wherein R^j and R^k are C_{1-10} alkyl;

or R^9 and R^{10} are joined together with the nitrogen atom to which they are attached to form



wherein w is 1, 2 or 3, and

R^{23} is selected from the group consisting of

- (a) hydrogen,
- (b) $-C_{1-10}$ alkyl,
- (c) $-C_{3-8}$ cycloalkyl,
- (d) $-C_{2-10}$ alkenyl,
- (e) $-C_{2-10}$ alkynyl,
- (f) $-(CH_2)_p$ -phenyl,

(g) $-(CH_2)_p$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl,

wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) $-C_{1-10}$ alkyl,
- (iii) $-OH$,
- (iv) $-CN$,
- (v) $-C_{3-8}$ cycloalkyl, or
- (vi) $-O-C_{1-10}$ alkyl;

R^{11} is selected from the group consisting of

- (1) $-CH-$
- (2) $-CH_2-$,
- (3) $-O-$, and
- (4) $-NR^{17}-$,

provided that when R^{11} is $-CH-$ the dotted line forms a bond and when R^{11} is $-CH_2-$, $-O-$ or $-NR^{17}-$ the dotted line is absent;


R^{17} is hydrogen or C_{1-10} alkyl, wherein said C_{1-10} alkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) $-OH$,
- (c) $-CN$,
- (d) $-C_{3-8}$ cycloalkyl,
- (e) $-O-C_{1-10}$ alkyl,
- (f) $-(CH_2)_q$ -phenyl, wherein q is 1 or 2, and
- (g) $-NR^{18}R^{19}$, and

wherein R¹⁸ and R¹⁹ are independently selected from the group consisting of

- (i) hydrogen, or
- (ii) C₁₋₁₀ alkyl;

or R¹⁸ and R¹⁹, together with the nitrogen atom to which they are attached, form the group



wherein q' is 1 or 2, Y⁷ is -CHR²⁴, -O- or NR²⁴, wherein R²⁴ is selected from the group consisting of;

- (a) hydrogen, and
- (b) C₁₋₁₀ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl, or
- (v) -C₃₋₈ cycloalkyl;

R²⁶ is selected from the group consisting of

- (1) hydrogen,
- (2) -C₁₋₃ alkyl;

R¹² is selected from the group consisting of

- (1) hydrogen,
- (2) -C₁₋₁₀ alkyl, wherein said alkyl is unsubstituted or substituted with one or more
 - (a) halo,
 - (b) -OH,
 - (c) -CN,
 - (d) -C₃₋₈ cycloalkyl,
 - (e) -O-C₁₋₁₀ alkyl, or
 - (f) -NH₂,

- (3) halo,
- (4) -C₃₋₈ cycloalkyl,
- (5) aryl selected from the group consisting of phenyl and naphthyl, and
- (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said aryl and heteroaryl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C₁₋₁₀ alkyl,
- (e) -C₃₋₈ cycloalkyl, or
- (f) -C₁₋₁₀ alkyl;

R¹³ is selected from the group consisting of

- (1) hydrogen,
- (2) C₁₋₁₀ alkyl, and
- (3) -C₃₋₈ cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C₃₋₈ cycloalkyl,
- (e) -O-C₁₋₁₀ alkyl, and
- (f) -C₁₋₁₀ alkyl;

R¹⁴ is selected from the group consisting of

- (1) -C₁₋₁₀ alkyl, and
- (2) -C₃₋₈ cycloalkyl;


wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,

- (d) $-C_{3-8}$ cycloalkyl,
 - (e) $-O-C_{1-10}$ alkyl, or
 - (f) $-C_{1-10}$ alkyl;
- (3) $-(CH_2)_v-NR^{15}R^{16}$, wherein v is 2, 3 or 4, and
wherein R^{15} and R^{16} are independently selected from the group
consisting of

- a) hydrogen, or
- b) C_{1-10} alkyl, wherein said C_{1-10} alkyl is
unsubstituted or substituted with one or more
 - (i) halo,
 - (ii) $-OH$,
 - (iii) $-CN$,
 - (iv) $-C_{3-8}$ cycloalkyl, or
 - (v) $-O-C_{1-10}$ alkyl;

or R^{15} and R^{16} , together with the nitrogen atom to which they are
attached, form the group



wherein s is 1 or 2, Y^4 is $-CHR^{24}-$, $-O-$ or $-NR^{24}-$, wherein R^{24} is selected from
the group consisting of

- (i) hydrogen, and
- (ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more


- (A) halo,
- (B) $-OH$,
- (C) $-CN$,
- (D) $-O-C_{1-10}$ alkyl, or
- (E) $-C_{3-8}$ cycloalkyl,

- 4) $-(CH_2)_r$ -phenyl, wherein r is 1, 2, 3, or 4, and
wherein said phenyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) $-OH$,

- (c) -CN,
- (d) -O-C₁₋₁₀ alkyl,
- (e) -C₃₋₈ cycloalkyl, or
- (f) -C₁₋₁₀ alkyl;

or R¹³ and R¹⁴, together with the nitrogen atom to which they are attached, form the group



wherein u is 1 or 2, Y⁸ is -CHR²⁵-, -O- or -NR²⁵-, wherein R²⁵ is selected from the group consisting of

- (a) hydrogen,
- (b) C₁₋₁₀ alkyl,
- (c) -(CH₂)_t-phenyl,
- (d) -(CH₂)_t-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -C₁₋₁₀ alkyl,
- (iii) -OH,
- (iv) -CN,
- (v) -C₃₋₈ cycloalkyl, or
- (vi) -O-C₁₋₁₀ alkyl;

and pharmaceutically acceptable salts thereof.

2. (Original) The compound of Claim 1 wherein R^a and R^b are both hydrogen.

3. (Original) The compound of Claim 1 wherein R^a is hydrogen and R^b is C_{1-10} alkyl.


4. (Original) The compound of Claim 1 wherein m is 1 and R^1 is selected from the group consisting of

- (1) phenyl, unsubstituted or substituted in one or two positions with halo; and
- (2) thienyl.

5. (Original) The compound of Claim 1 wherein R^2 is $(R^4-SO_2)N(R^7)-$.


6. (Original) The compound of Claim 5 wherein R^4 and R^7 are each C_{1-6} alkyl.

7. (Original) The compound of Claim 1 wherein R^3 is (1)




wherein Y^3 is CHR^{6c} , R^5 is methyl, R^{6a} and R^{6c} are hydrogen and R^{6b} is fluoro.

8. (Original) The compound of Claim 1 wherein R^3 is (1)




Y^3 is N, R^5 is C_{1-2} perfluoroalkyl, and R^{6a} and R^{6b} are hydrogen.

9. (Original) The compound of Claim 1 wherein R^3 is (2)




and R⁹ and R¹⁰ are each unsubstituted C₁₋₁₀ alkyl, or R⁹ and R¹⁰ are joined together with the nitrogen atom to which they are attached to form attached to form



wherein w is 1;


R²³ is $-(CH_2)_p$ -phenyl or $-(CH_2)_p$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl, wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more chloro, and p is 0.

10. (Original) The compound of Claim 1 wherein R³ is (3)




R¹¹ is NR¹⁷ wherein R¹⁷ is hydrogen or C₁₋₃ alkyl, and R¹² is hydrogen or methyl.

11. (Original) The compound of Claim 1 wherein R³ is (4)




R¹³ is hydrogen and R¹⁴ is $-(CH_2)_v$ -NR¹⁵R¹⁶ wherein v is 2 and R¹⁵ and R¹⁶ are each C₁₋₁₀ alkyl, which is unsubstituted or substituted with -OH, -CN or -OCH₃.

12. (Original) The compound of Claim 1 wherein R³ is (4)




wherein R¹³ and R¹⁴, together with the nitrogen atom to which they are attached, form the group




wherein u is 1 or 2, Y⁸ is -CHR²⁵-, -O- or -NR²⁵-.

13. (Original) The compound of Claim 1 which is a compound of formula (II)




wherein Q¹, Q², Q³, R^a, R^b, R¹, R², R¹², R¹⁷, R²⁶ and m are as defined in Claim 1, and pharmaceutically acceptable salts thereof.

14. (Original) The compound of Claim 1 which is a compound of formula (III)




wherein Q¹, Q², Q³, R^a, R^b, R¹, R², R¹³, R¹⁴ and m are defined as in Claim 1, and pharmaceutically acceptable salts thereof.











15. (Original) The compound of Claim 1 which is a compound of formula (IV):























wherein Q¹, Q², Q³, R^a, R^b, R¹, R² and m are as defined in Claim 1, and R³ is (1) or (2) as defined in Claim 1, and pharmaceutically acceptable salts thereof.











16. (Amended) A compound of claim 1 which is selected from the group consisting of














	
	
	
	
	


	
	
	
	
	


	
	
	
	
	


	
	
	
	
	





	
	
	
	
	


























and pharmaceutically acceptable salts thereof.

17. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

18. (Canceled)

19. (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1.

20. (Canceled)